This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (4)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Eugene Mandrea, MD
8625 S Cicero Ave Chicago

Arch Dermatol. 1971;103(5):560-561.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

The immunologic approach to treatment of cancer and precancerous lesions is relatively new. It consists of enhancing the cellular immune mechanisms of the host in order to obtain rejection of the neoplasm. In recent years nonspecific agents have been used to stimulate the host's immune system. BCG vaccine has been used with limited success in acute leukemia¹ and in malignant melanoma (Medical Tribune 1, 1970). Ratner and associates have used 2-4-dinitrochlorobenzene in mycosis fungoides with some success,² although recurrence of lesions or development of new ones was almost always seen within months.³ In a more recent communication⁴ Van Scott and Winters reported complete remissions of from two to nine months in 11 of 14 patients with plaque stage of mycosis fungoides and in 3 of 4 patients with generalized erythema who had been treated with mechlorethamine hydrochloride (nitrogen mustard) topically. The best results . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?